What Type of Patients Did PARAGON-HF Select? Insights from a Real-World Prospective Cohort of Patients with Heart Failure and Preserved Ejection Fraction

The PARAGON-HF clinical trial suggested that sacubitril/valsartan may become a treatment option for particular subgroups of patients with heart failure and preserved ejection fraction (HFpEF). However, the proportion of real-world HFpEF patients who are theoretically superimposable with the PARAGON-...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of clinical medicine 2020-11, Vol.9 (11), p.3669
Hauptverfasser:	Rettl, René, Dachs, Theresa-Marie, Duca, Franz, Binder, Christina, Dusik, Fabian, Seirer, Benjamin, Schönauer, Johannes, Kronberger, Christina, Camuz Ligios, Luciana, Hengstenberg, Christian, Derkits, Nina, Kastner, Johannes, Badr Eslam, Roza, Bonderman, Diana
Format:	Artikel
Sprache:	eng
Schlagworte:	Cardiology Cardiovascular disease Clinical medicine Clinical outcomes Ejection fraction Females Genotype & phenotype Heart failure Hospitalization Hypertension Laboratories Pathophysiology Patient safety Pulmonary arteries Variance analysis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!